Use of Opioids at High Dosage in Persons without Cancer (OHD)
(NQF-Endorsed Jan 2017 - #2940)

Proportion (XX out of 1,000) of individuals from the denominator receiving prescriptions for
opioids with a daily dosage >120 morphine milligram equivalents (MME) for ≥90
consecutive days. (Excludes patients in hospice care and those with cancer.)

Note: PQA is currently testing revised specifications with a threshold of ≥90 MME for implementation in 2019.

Use: Medicaid Adult Core Set since 2016; Medicare Part D Patient Safety reports since 2016

Use of Opioids from Multiple Providers in Persons without Cancer (OMP)
(NQF-Endorsed January 2017 - #2950)

Proportion (XX out of 1,000) of individuals from the denominator receiving prescriptions for
opioids from ≥4 prescribers AND ≥4 pharmacies.
(Excludes patients in hospice care and those with cancer.)

Use: Medicare Part D Patient Safety reports since 2016

Use of Opioids at High Dosage and from Multiple Providers in Persons
without Cancer (OHDMP)
(NQF Endorsement January 2017 - #2951)

Proportion (XX out of 1,000) of individuals from the denominator receiving prescriptions for
opioids with a daily dosage >120 morphine milligram equivalents (MME) for ≥90 consecutive
days, AND who received opioid prescriptions from ≥4 prescribers AND ≥4 pharmacies.
(Excludes patients in hospice care and those with cancer.)

Use: Medicare Part D Patient Safety reports since 2016; planned for 2019 Part D display page (2017 data)

Concurrent Use of Opioids and Benzodiazepines (COB)
(NQF endorsement submission in progress)

Percentage of individuals 18 years and older with concurrent use of prescription opioids and
benzodiazepines for 30 or more cumulative days. (Excludes patients in hospice care and those with cancer.)

Use: 2018 Medicaid Adult Core Set; Medicare Part D Patient Safety reports
for 2018, and planned for Part D display page for 2021 (2019 data) and 2022 (2020 data)

Initial Opioid Prescribing
(3 related measure concepts)

Percentage of patients 18 years and older with initial opioid prescription for:
• Long-acting/extended release opioid
• ≥50 MME/day
• >7 days’ supply

Status: Expedited development in 2018